APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Human Plasma-derived Hyperimmune Product

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Human Plasma-derived Hyperimmune Product Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174000010321 December 2025199 pages

Choose your research edition.

Industry ResearchHuman Plasma-derived Hyperimmune Product Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Plasma-derived Hyperimmune Product Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Human Plasma-derived Hyperimmune Product Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Plasma-derived Hyperimmune Product Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Plasma-derived Hyperimmune Product Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Human Plasma-derived Hyperimmune Product market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Human Plasma-derived Hyperimmune Product is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Plasma-derived Hyperimmune Product is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Plasma-derived Hyperimmune Product is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Human Plasma-derived Hyperimmune Product is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Human Plasma-derived Hyperimmune Product include Sichuan Yuanda Shuyang, Shanghai RAAS, Grifols, Hualan Bio, Kedrion, Kamada, Emergent (Cangene), CSL Behring and CNBG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human Plasma-derived Hyperimmune Product market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Plasma-derived Hyperimmune Product and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Plasma-derived Hyperimmune Product sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Plasma-derived Hyperimmune Product market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Plasma-derived Hyperimmune Product Segment by Company

Sichuan Yuanda Shuyang

Shanghai RAAS

Grifols

Hualan Bio

Kedrion

Kamada

Emergent (Cangene)

CSL Behring

CNBG

CBPO

Biotest

ADMA Biologics

Human Plasma-derived Hyperimmune Product Segment by Type

Rho(D) Immunoglobulins

Rabies Immunoglobulins

Tetanus Immunoglobulins

Hepatitis B Immunoglobulins

Other

Human Plasma-derived Hyperimmune Product Segment by Application

Government Institution

Private Sector

Others

Human Plasma-derived Hyperimmune Product Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Plasma-derived Hyperimmune Product market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Plasma-derived Hyperimmune Product and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Plasma-derived Hyperimmune Product.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Plasma-derived Hyperimmune Product market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Human Plasma-derived Hyperimmune Product manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Human Plasma-derived Hyperimmune Product in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Human Plasma-derived Hyperimmune Product in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Human Plasma-derived Hyperimmune Product Industry Trends Table 2. Human Plasma-derived Hyperimmune Product Industry Drivers Table 3. Human Plasma-derived Hyperimmune Product Industry Opportunities and Challenges Table 4. Human Plasma-derived Hyperimmune Product Industry Restraints Table 5. Global Human Plasma-derived Hyperimmune Product Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Human Plasma-derived Hyperimmune Product Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Manufacturers Table 9. Global Human Plasma-derived Hyperimmune Product Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Human Plasma-derived Hyperimmune Product Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Human Plasma-derived Hyperimmune Product Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Human Plasma-derived Hyperimmune Product Manufacturers, Product Type & Application Table 13. Global Human Plasma-derived Hyperimmune Product Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Plasma-derived Hyperimmune Product by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Rho(D) Immunoglobulins Table 17. Major Manufacturers of Rabies Immunoglobulins Table 18. Major Manufacturers of Tetanus Immunoglobulins Table 19. Major Manufacturers of Hepatitis B Immunoglobulins Table 20. Major Manufacturers of Other Table 21. Global Human Plasma-derived Hyperimmune Product Sales by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Human Plasma-derived Hyperimmune Product Sales by Type (2021-2026) & (k units) Table 23. Global Human Plasma-derived Hyperimmune Product Sales by Type (2027-2032) & (k units) Table 24. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Type (2021-2026) Table 25. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Type (2027-2032) Table 26. Global Human Plasma-derived Hyperimmune Product Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global Human Plasma-derived Hyperimmune Product Revenue by Type (2021-2026) & (k units) Table 28. Global Human Plasma-derived Hyperimmune Product Revenue by Type (2027-2032) & (k units) Table 29. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Type (2021-2026) Table 30. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Government Institution Table 32. Major Manufacturers of Private Sector Table 33. Major Manufacturers of Others Table 34. Global Human Plasma-derived Hyperimmune Product Sales by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Human Plasma-derived Hyperimmune Product Sales by Application (2021-2026) & (k units) Table 36. Global Human Plasma-derived Hyperimmune Product Sales by Application (2027-2032) & (k units) Table 37. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Application (2021-2026) Table 38. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Application (2027-2032) Table 39. Global Human Plasma-derived Hyperimmune Product Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 40. Global Human Plasma-derived Hyperimmune Product Revenue by Application (2021-2026) & (k units) Table 41. Global Human Plasma-derived Hyperimmune Product Revenue by Application (2027-2032) & (k units) Table 42. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Application (2021-2026) Table 43. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Application (2027-2032) Table 44. Global Human Plasma-derived Hyperimmune Product Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Human Plasma-derived Hyperimmune Product Sales by Region (2021-2026) & (k units) Table 46. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Region (2021-2026) Table 47. Global Human Plasma-derived Hyperimmune Product Sales Forecasted by Region (2027-2032) & (k units) Table 48. Global Human Plasma-derived Hyperimmune Product Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Human Plasma-derived Hyperimmune Product Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. North America Human Plasma-derived Hyperimmune Product Sales by Country (2021-2026) & (k units) Table 51. North America Human Plasma-derived Hyperimmune Product Sales by Country (2027-2032) & (k units) Table 52. Europe Human Plasma-derived Hyperimmune Product Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Europe Human Plasma-derived Hyperimmune Product Sales by Country (2021-2026) & (k units) Table 54. Europe Human Plasma-derived Hyperimmune Product Sales by Country (2027-2032) & (k units) Table 55. Asia Pacific Human Plasma-derived Hyperimmune Product Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Asia Pacific Human Plasma-derived Hyperimmune Product Sales by Country (2021-2026) & (k units) Table 57. Asia Pacific Human Plasma-derived Hyperimmune Product Sales by Country (2027-2032) & (k units) Table 58. South America, Middle East and Africa Human Plasma-derived Hyperimmune Product Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 59. South America, Middle East and Africa Human Plasma-derived Hyperimmune Product Sales by Country (2021-2026) & (k units) Table 60. South America, Middle East and Africa Human Plasma-derived Hyperimmune Product Sales by Country (2027-2032) & (k units) Table 61. Global Human Plasma-derived Hyperimmune Product Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Human Plasma-derived Hyperimmune Product Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Human Plasma-derived Hyperimmune Product Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Region (2021-2026) Table 65. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Region (2027-2032) Table 66. Sichuan Yuanda Shuyang Company Information Table 67. Sichuan Yuanda Shuyang Business Overview Table 68. Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Product Portfolio Table 70. Sichuan Yuanda Shuyang Recent Development Table 71. Shanghai RAAS Company Information Table 72. Shanghai RAAS Business Overview Table 73. Shanghai RAAS Human Plasma-derived Hyperimmune Product Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Shanghai RAAS Human Plasma-derived Hyperimmune Product Product Portfolio Table 75. Shanghai RAAS Recent Development Table 76. Grifols Company Information Table 77. Grifols Business Overview Table 78. Grifols Human Plasma-derived Hyperimmune Product Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Grifols Human Plasma-derived Hyperimmune Product Product Portfolio Table 80. Grifols Recent Development Table 81. Hualan Bio Company Information Table 82. Hualan Bio Business Overview Table 83. Hualan Bio Human Plasma-derived Hyperimmune Product Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Hualan Bio Human Plasma-derived Hyperimmune Product Product Portfolio Table 85. Hualan Bio Recent Development Table 86. Kedrion Company Information Table 87. Kedrion Business Overview Table 88. Kedrion Human Plasma-derived Hyperimmune Product Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Kedrion Human Plasma-derived Hyperimmune Product Product Portfolio Table 90. Kedrion Recent Development Table 91. Kamada Company Information Table 92. Kamada Business Overview Table 93. Kamada Human Plasma-derived Hyperimmune Product Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Kamada Human Plasma-derived Hyperimmune Product Product Portfolio Table 95. Kamada Recent Development Table 96. Emergent (Cangene) Company Information Table 97. Emergent (Cangene) Business Overview Table 98. Emergent (Cangene) Human Plasma-derived Hyperimmune Product Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Emergent (Cangene) Human Plasma-derived Hyperimmune Product Product Portfolio Table 100. Emergent (Cangene) Recent Development Table 101. CSL Behring Company Information Table 102. CSL Behring Business Overview Table 103. CSL Behring Human Plasma-derived Hyperimmune Product Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. CSL Behring Human Plasma-derived Hyperimmune Product Product Portfolio Table 105. CSL Behring Recent Development Table 106. CNBG Company Information Table 107. CNBG Business Overview Table 108. CNBG Human Plasma-derived Hyperimmune Product Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. CNBG Human Plasma-derived Hyperimmune Product Product Portfolio Table 110. CNBG Recent Development Table 111. CBPO Company Information Table 112. CBPO Business Overview Table 113. CBPO Human Plasma-derived Hyperimmune Product Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. CBPO Human Plasma-derived Hyperimmune Product Product Portfolio Table 115. CBPO Recent Development Table 116. Biotest Company Information Table 117. Biotest Business Overview Table 118. Biotest Human Plasma-derived Hyperimmune Product Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Biotest Human Plasma-derived Hyperimmune Product Product Portfolio Table 120. Biotest Recent Development Table 121. ADMA Biologics Company Information Table 122. ADMA Biologics Business Overview Table 123. ADMA Biologics Human Plasma-derived Hyperimmune Product Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. ADMA Biologics Human Plasma-derived Hyperimmune Product Product Portfolio Table 125. ADMA Biologics Recent Development Table 126. Key Raw Materials Table 127. Raw Materials Key Suppliers Table 128. Human Plasma-derived Hyperimmune Product Distributors List Table 129. Human Plasma-derived Hyperimmune Product Customers List Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Human Plasma-derived Hyperimmune Product Product Image Figure 2. Global Human Plasma-derived Hyperimmune Product Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Plasma-derived Hyperimmune Product Market Size (2021-2032) & (US$ Million) Figure 4. Global Human Plasma-derived Hyperimmune Product Sales (2021-2032) & (k units) Figure 5. Global Human Plasma-derived Hyperimmune Product Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Human Plasma-derived Hyperimmune Product Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Rho(D) Immunoglobulins Image Figure 9. Rabies Immunoglobulins Image Figure 10. Tetanus Immunoglobulins Image Figure 11. Hepatitis B Immunoglobulins Image Figure 12. Other Image Figure 13. Global Human Plasma-derived Hyperimmune Product Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Human Plasma-derived Hyperimmune Product Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Type (2021-2032) Figure 16. Global Human Plasma-derived Hyperimmune Product Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Human Plasma-derived Hyperimmune Product Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Type (2021-2032) Figure 19. Government Institution Image Figure 20. Private Sector Image Figure 21. Others Image Figure 22. Global Human Plasma-derived Hyperimmune Product Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Human Plasma-derived Hyperimmune Product Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Application (2021-2032) Figure 25. Global Human Plasma-derived Hyperimmune Product Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Human Plasma-derived Hyperimmune Product Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Application (2021-2032) Figure 28. North America Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 29. North America Human Plasma-derived Hyperimmune Product Sales Market Share by Country (2021-2032) Figure 30. U.S. Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 31. Canada Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 32. Mexico Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Human Plasma-derived Hyperimmune Product Sales Market Share by Country (2021-2032) Figure 35. Germany Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 36. France Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 37. U.K. Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 38. Italy Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 39. Netherlands Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Human Plasma-derived Hyperimmune Product Sales Market Share by Country (2021-2032) Figure 42. China Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 43. Japan Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 44. South Korea Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 45. Southeast Asia Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 46. India Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 47. Australia Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Human Plasma-derived Hyperimmune Product Sales Market Share by Country (2021-2032) Figure 50. Brazil Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 51. South Africa Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 52. Saudi Arabia Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 53. Turkey Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 54. Argentina Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 55. UAE Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 56. Egypt Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 57. Chile Human Plasma-derived Hyperimmune Product Sales and Growth Rate (2021-2032) & (k units) Figure 58. Global Human Plasma-derived Hyperimmune Product Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Figure 61. North America Human Plasma-derived Hyperimmune Product Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Figure 63. Europe Human Plasma-derived Hyperimmune Product Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Human Plasma-derived Hyperimmune Product Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Human Plasma-derived Hyperimmune Product Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Human Plasma-derived Hyperimmune Product Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Human Plasma-derived Hyperimmune Product Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Human Plasma-derived Hyperimmune Product Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Rho(D) Immunoglobulins
  • Rabies Immunoglobulins
  • Tetanus Immunoglobulins
  • Hepatitis B Immunoglobulins
  • Other
Applications
  • Government Institution
  • Private Sector
  • Others
Companies covered
  • Sichuan Yuanda Shuyang
  • Shanghai RAAS
  • Grifols
  • Hualan Bio
  • Kedrion
  • Kamada
  • Emergent (Cangene)
  • CSL Behring
  • CNBG
  • CBPO
  • Biotest
  • ADMA Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human Plasma-derived Hyperimmune Product Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human Plasma-derived Hyperimmune Product Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Human Plasma-derived Hyperimmune Product Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Human Plasma-derived Hyperimmune Product Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Human Plasma-derived Hyperimmune Product Market Dynamics
  1. 2.1 Human Plasma-derived Hyperimmune Product Industry Trends
  2. 2.2 Human Plasma-derived Hyperimmune Product Industry Drivers
  3. 2.3 Human Plasma-derived Hyperimmune Product Industry Opportunities and Challenges
  4. 2.4 Human Plasma-derived Hyperimmune Product Industry Restraints
3 Human Plasma-derived Hyperimmune Product Market by Manufacturers
  1. 3.1 Global Human Plasma-derived Hyperimmune Product Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Human Plasma-derived Hyperimmune Product Sales by Manufacturers (2021-2026)
  3. 3.3 Global Human Plasma-derived Hyperimmune Product Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Human Plasma-derived Hyperimmune Product Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Human Plasma-derived Hyperimmune Product Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Human Plasma-derived Hyperimmune Product Manufacturers, Product Type & Application
  7. 3.7 Global Human Plasma-derived Hyperimmune Product Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Human Plasma-derived Hyperimmune Product Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Human Plasma-derived Hyperimmune Product Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Human Plasma-derived Hyperimmune Product Tier 1, Tier 2, and Tier 3
4 Human Plasma-derived Hyperimmune Product Market by Type
  1. 4.1 Human Plasma-derived Hyperimmune Product Type Introduction
  2. 4.1.1 Rho(D) Immunoglobulins
  3. 4.1.2 Rabies Immunoglobulins
  4. 4.1.3 Tetanus Immunoglobulins
  5. 4.1.4 Hepatitis B Immunoglobulins
  6. 4.1.5 Other
  7. 4.2 Global Human Plasma-derived Hyperimmune Product Sales by Type
  8. 4.2.1 Global Human Plasma-derived Hyperimmune Product Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Human Plasma-derived Hyperimmune Product Sales by Type (2021-2032)
  10. 4.2.3 Global Human Plasma-derived Hyperimmune Product Sales Market Share by Type (2021-2032)
  11. 4.3 Global Human Plasma-derived Hyperimmune Product Revenue by Type
  12. 4.3.1 Global Human Plasma-derived Hyperimmune Product Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Human Plasma-derived Hyperimmune Product Revenue by Type (2021-2032)
  14. 4.3.3 Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Type (2021-2032)
5 Human Plasma-derived Hyperimmune Product Market by Application
  1. 5.1 Human Plasma-derived Hyperimmune Product Application Introduction
  2. 5.1.1 Government Institution
  3. 5.1.2 Private Sector
  4. 5.1.3 Others
  5. 5.2 Global Human Plasma-derived Hyperimmune Product Sales by Application
  6. 5.2.1 Global Human Plasma-derived Hyperimmune Product Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Human Plasma-derived Hyperimmune Product Sales by Application (2021-2032)
  8. 5.2.3 Global Human Plasma-derived Hyperimmune Product Sales Market Share by Application (2021-2032)
  9. 5.3 Global Human Plasma-derived Hyperimmune Product Revenue by Application
  10. 5.3.1 Global Human Plasma-derived Hyperimmune Product Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Human Plasma-derived Hyperimmune Product Revenue by Application (2021-2032)
  12. 5.3.3 Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Application (2021-2032)
6 Global Human Plasma-derived Hyperimmune Product Sales by Region
  1. 6.1 Global Human Plasma-derived Hyperimmune Product Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Plasma-derived Hyperimmune Product Sales by Region (2021-2032)
  3. 6.2.1 Global Human Plasma-derived Hyperimmune Product Sales by Region (2021-2026)
  4. 6.2.2 Global Human Plasma-derived Hyperimmune Product Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human Plasma-derived Hyperimmune Product Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Human Plasma-derived Hyperimmune Product Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Human Plasma-derived Hyperimmune Product Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Human Plasma-derived Hyperimmune Product Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Human Plasma-derived Hyperimmune Product Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Human Plasma-derived Hyperimmune Product Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Human Plasma-derived Hyperimmune Product Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Human Plasma-derived Hyperimmune Product Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Human Plasma-derived Hyperimmune Product Revenue by Region
  1. 7.1 Global Human Plasma-derived Hyperimmune Product Revenue by Region
  2. 7.1.1 Global Human Plasma-derived Hyperimmune Product Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Human Plasma-derived Hyperimmune Product Revenue by Region (2021-2026)
  4. 7.1.3 Global Human Plasma-derived Hyperimmune Product Revenue by Region (2027-2032)
  5. 7.1.4 Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Human Plasma-derived Hyperimmune Product Revenue (2021-2032)
  8. 7.2.2 North America Human Plasma-derived Hyperimmune Product Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Human Plasma-derived Hyperimmune Product Revenue (2021-2032)
  11. 7.3.2 Europe Human Plasma-derived Hyperimmune Product Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Human Plasma-derived Hyperimmune Product Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Human Plasma-derived Hyperimmune Product Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Human Plasma-derived Hyperimmune Product Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Human Plasma-derived Hyperimmune Product Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sichuan Yuanda Shuyang
  2. 8.1.1 Sichuan Yuanda Shuyang Company Information
  3. 8.1.2 Sichuan Yuanda Shuyang Business Overview
  4. 8.1.3 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Product Portfolio
  6. 8.1.5 Sichuan Yuanda Shuyang Recent Developments
  7. 8.2 Shanghai RAAS
  8. 8.2.1 Shanghai RAAS Company Information
  9. 8.2.2 Shanghai RAAS Business Overview
  10. 8.2.3 Shanghai RAAS Human Plasma-derived Hyperimmune Product Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Shanghai RAAS Human Plasma-derived Hyperimmune Product Product Portfolio
  12. 8.2.5 Shanghai RAAS Recent Developments
  13. 8.3 Grifols
  14. 8.3.1 Grifols Company Information
  15. 8.3.2 Grifols Business Overview
  16. 8.3.3 Grifols Human Plasma-derived Hyperimmune Product Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Grifols Human Plasma-derived Hyperimmune Product Product Portfolio
  18. 8.3.5 Grifols Recent Developments
  19. 8.4 Hualan Bio
  20. 8.4.1 Hualan Bio Company Information
  21. 8.4.2 Hualan Bio Business Overview
  22. 8.4.3 Hualan Bio Human Plasma-derived Hyperimmune Product Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Hualan Bio Human Plasma-derived Hyperimmune Product Product Portfolio
  24. 8.4.5 Hualan Bio Recent Developments
  25. 8.5 Kedrion
  26. 8.5.1 Kedrion Company Information
  27. 8.5.2 Kedrion Business Overview
  28. 8.5.3 Kedrion Human Plasma-derived Hyperimmune Product Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Kedrion Human Plasma-derived Hyperimmune Product Product Portfolio
  30. 8.5.5 Kedrion Recent Developments
  31. 8.6 Kamada
  32. 8.6.1 Kamada Company Information
  33. 8.6.2 Kamada Business Overview
  34. 8.6.3 Kamada Human Plasma-derived Hyperimmune Product Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Kamada Human Plasma-derived Hyperimmune Product Product Portfolio
  36. 8.6.5 Kamada Recent Developments
  37. 8.7 Emergent (Cangene)
  38. 8.7.1 Emergent (Cangene) Company Information
  39. 8.7.2 Emergent (Cangene) Business Overview
  40. 8.7.3 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Product Portfolio
  42. 8.7.5 Emergent (Cangene) Recent Developments
  43. 8.8 CSL Behring
  44. 8.8.1 CSL Behring Company Information
  45. 8.8.2 CSL Behring Business Overview
  46. 8.8.3 CSL Behring Human Plasma-derived Hyperimmune Product Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 CSL Behring Human Plasma-derived Hyperimmune Product Product Portfolio
  48. 8.8.5 CSL Behring Recent Developments
  49. 8.9 CNBG
  50. 8.9.1 CNBG Company Information
  51. 8.9.2 CNBG Business Overview
  52. 8.9.3 CNBG Human Plasma-derived Hyperimmune Product Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 CNBG Human Plasma-derived Hyperimmune Product Product Portfolio
  54. 8.9.5 CNBG Recent Developments
  55. 8.10 CBPO
  56. 8.10.1 CBPO Company Information
  57. 8.10.2 CBPO Business Overview
  58. 8.10.3 CBPO Human Plasma-derived Hyperimmune Product Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 CBPO Human Plasma-derived Hyperimmune Product Product Portfolio
  60. 8.10.5 CBPO Recent Developments
  61. 8.11 Biotest
  62. 8.11.1 Biotest Company Information
  63. 8.11.2 Biotest Business Overview
  64. 8.11.3 Biotest Human Plasma-derived Hyperimmune Product Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Biotest Human Plasma-derived Hyperimmune Product Product Portfolio
  66. 8.11.5 Biotest Recent Developments
  67. 8.12 ADMA Biologics
  68. 8.12.1 ADMA Biologics Company Information
  69. 8.12.2 ADMA Biologics Business Overview
  70. 8.12.3 ADMA Biologics Human Plasma-derived Hyperimmune Product Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 ADMA Biologics Human Plasma-derived Hyperimmune Product Product Portfolio
  72. 8.12.5 ADMA Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Plasma-derived Hyperimmune Product Value Chain Analysis
  2. 9.1.1 Human Plasma-derived Hyperimmune Product Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Plasma-derived Hyperimmune Product Production Mode & Process
  6. 9.2 Human Plasma-derived Hyperimmune Product Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Plasma-derived Hyperimmune Product Distributors
  9. 9.2.3 Human Plasma-derived Hyperimmune Product Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst